{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:23:25Z","timestamp":1787660605606,"version":"build-2736575974"},"reference-count":68,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Neoadjuvant immune checkpoint blockade has produced high pathological and clinical response rates in mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer, raising the possibility of response-adapted organ preservation. However, the evidence is anatomically uneven and remains immature for routine surgery avoidance. In dMMR colon cancer, neoadjuvant studies primarily establish drug activity through resection-confirmed pathological and nodal response; reliable criteria for nonoperative assessment have not been validated. In dMMR rectal cancer, clinical complete response (cCR) after PD-1 blockade may support watch-and-wait in highly selected patients because local response can be reassessed using digital rectal examination, endoscopy, pelvic MRI, biopsy when appropriate, systemic imaging, and tumor markers. This narrative review critically appraises the biological rationale, prospective and observational evidence, response-assessment limitations, surgical decision points, surveillance requirements, toxicity, and unresolved controversies surrounding organ preservation after neoadjuvant immunotherapy. We use the term immune-response-adapted surgical deferral to emphasize that surgery remains available for incomplete response, unresolved uncertainty, or regrowth. Current implementation should be confined to experienced multidisciplinary programs with rigorous molecular confirmation, standardized multimodal assessment, reliable follow-up, informed patient participation, and timely salvage capacity. Particular attention is given to immunotherapy-specific uncertainty in defining durable cCR, the limitations of circulating tumor DNA (ctDNA) as a stand-alone local decision tool, hereditary-risk considerations in Lynch syndrome, and the need for location-specific prospective validation.<\/jats:p>","DOI":"10.3389\/fonc.2026.1908199","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:40:25Z","timestamp":1787658025000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Organ preservation after neoadjuvant immunotherapy in mismatch repair-deficient colorectal cancer: response assessment, watch-and-wait, and salvage surgery"],"prefix":"10.3389","volume":"16","author":[{"given":"Nan","family":"Yao","sequence":"first","affiliation":[{"name":"Department of General Surgery, Aerospace Center Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoshuai","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Aerospace Center Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Aerospace Center Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuzhou","family":"Han","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Aerospace Center Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Aerospace Center Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Aerospace Center Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1053\/j.gastro.2020.02.068","article-title":"Global burden of 5 major types of gastrointestinal cancer","volume":"159","author":"Arnold","year":"2020","journal-title":"Gastroenterology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800691019","article-title":"The mesorectum in rectal cancer surgery-the clue to pelvic recurrence","volume":"69","author":"Heald","year":"1982","journal-title":"Br J Surg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer","volume":"351","author":"Sauer","year":"2004","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/01.sla.0000141194.27992.32","article-title":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results","volume":"240","author":"Habr-Gama","year":"2004","journal-title":"Ann Surg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31078-x","article-title":"Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study","volume":"391","author":"van der Valk","year":"2018","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00032","article-title":"Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy","volume":"40","author":"Garcia-Aguilar","year":"2022","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01208","article-title":"Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial","volume":"42","author":"Verheij","year":"2024","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.01160","article-title":"Management of locally advanced rectal cancer: ASCO guideline","volume":"42","author":"Scott","year":"2024","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022289","article-title":"Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer","volume":"349","author":"Ribic","year":"2003","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.1825","article-title":"Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer","volume":"28","author":"Sargent","year":"2010","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402141","article-title":"Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer","volume":"391","author":"Andr\u00e9","year":"2024","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2201445","article-title":"PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404512","article-title":"Nonoperative management of mismatch repair-deficient tumors","volume":"392","author":"Cercek","year":"2025","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1053\/j.gastro.2009.12.064","article-title":"Microsatellite instability in colorectal cancer","volume":"138","author":"Boland","year":"2010","journal-title":"Gastroenterology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4191","article-title":"Classification and characterization of microsatellite instability across 18 cancer types","volume":"22","author":"Hause","year":"2016","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","year":"2012","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13059-015-0620-6","article-title":"Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy","volume":"16","author":"Angelova","year":"2015","journal-title":"Genome Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.30.5425","article-title":"Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction","volume":"29","author":"Mlecnik","year":"2011","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30789-X","article-title":"International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study","volume":"391","author":"Pag\u00e8s","year":"2018","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-16-0577","article-title":"Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105516","article-title":"Neoadjuvant immunotherapy for nonmetastatic dMMR\/MSI colon cancer: a real-world retrospective AGEO study","volume":"10","author":"Lemaire","year":"2025","journal-title":"ESMO Open"},{"key":"B31","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s12029-025-01358-x","article-title":"Neoadjuvant immune checkpoint inhibition in MSI-H\/dMMR colorectal cancer: a systematic review of prospective trials evaluating efficacy, pathologic response, and surgical outcomes","volume":"56","author":"Mirza","year":"2025","journal-title":"J Gastrointest Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00203-1","article-title":"Neoadjuvant camrelizumab plus apatinib for locally advanced microsatellite instability-high or mismatch repair-deficient colorectal cancer (NEOCAP): a single-arm, open-label, phase 2 study","volume":"25","author":"Yu","year":"2024","journal-title":"Lancet Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/s2468-1253(21)00348-4","article-title":"Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial","volume":"7","author":"Hu","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA3504","article-title":"NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high-risk stage 2 or stage 3 deficient-MMR\/MSI-high colorectal cancer","volume":"42","author":"Shiu","year":"2024","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4687-9","article-title":"Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: selection for organ-saving treatment","volume":"22","author":"Maas","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/02841851211065925","article-title":"Diagnostic performance of MRI and endoscopy for assessing complete response in rectal cancer after neoadjuvant chemoradiotherapy: a systematic review of the literature","volume":"64","author":"Munk","year":"2023","journal-title":"Acta Radiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.28","article-title":"Diagnostic performance of endoscopy and MRI in identifying true response among patients with rectal cancer treated with total neoadjuvant therapy and selective watch and wait or TME","volume":"42","author":"Omer","year":"2024","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.221529","article-title":"Watch-and-wait approach to rectal cancer: the role of imaging","volume":"307","author":"Jayaprakasam","year":"2023","journal-title":"Radiology"},{"key":"B39","unstructured":"Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair-Deficient Solid Tumors. NCT04165772"},{"key":"B40","unstructured":"Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers"},{"key":"B41","unstructured":"PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR\/MSI-H Colorectal Cancer"},{"key":"B42","unstructured":"Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR\/MSI-H Localized Colon Cancer: PREMICES Study"},{"key":"B43","unstructured":"The Efficacy of Watch and Wait Strategy or Surgery After Neoadjuvant Immunotherapy for Locally Advanced Colorectal Cancer With dMMR\/MSI-H Guided by MRD Dynamic Monitoring: A Single-center, Open-label, Prospective, Phase II Clinical Trial"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.3559","article-title":"The efficacy of watch-and-wait strategy or surgery after neoadjuvant immunotherapy for locally advanced colorectal cancer with dMMR\/MSI-H guided by ctDNA dynamic monitoring (WINDOW): a single-center, open-label, prospective, phase II study","volume":"43","author":"Zhang","year":"2025","journal-title":"J Clin Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(17)30074-2","article-title":"A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis","volume":"2","author":"Dossa","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0b013e3182759f1c","article-title":"Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy","volume":"256","author":"Smith","year":"2012","journal-title":"Ann Surg"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)00467-2","article-title":"Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis","volume":"17","author":"Renehan","year":"2016","journal-title":"Lancet Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)00120-5","article-title":"High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study","volume":"16","author":"Appelt","year":"2015","journal-title":"Lancet Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci Transl Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02115-4","article-title":"Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer","volume":"29","author":"Kotani","year":"2023","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18050815","article-title":"Circulating tumour DNA after neoadjuvant therapy in non-metastatic colon cancer: a systematic review and implications for surgical decision-making","volume":"18","author":"Salama","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11894-020-00785-z","article-title":"Low anterior resection syndrome","volume":"22","author":"Nguyen","year":"2020","journal-title":"Curr Gastroenterol Rep"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030778","article-title":"Management of Low Anterior Resection Syndrome (LARS) Following Resection for Rectal Cancer","volume":"15","author":"Rosen","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2023.0146","article-title":"Long-term quality of life and functional outcome of patients with rectal cancer following a watch-and-wait approach","volume":"158","author":"Custers","year":"2023","journal-title":"JAMA Surg"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00943-6","article-title":"Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response","volume":"21","author":"Williams","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-304356","article-title":"Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts","volume":"62","author":"Vasen","year":"2013","journal-title":"Gut"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh034","article-title":"Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability","volume":"96","author":"Umar","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.11902","article-title":"European guidelines from the EHTG and ESCP for Lynch syndrome: an updated third edition of the Mallorca guidelines based on gene and gender","volume":"108","author":"Sepp\u00e4l\u00e4","year":"2021","journal-title":"Br J Surg"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-025-02892-1","article-title":"Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2024 for the clinical practice of hereditary colorectal cancer","volume":"31","author":"Tanakaya","year":"2026","journal-title":"Int J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"55","DOI":"10.7326\/M14-0697","article-title":"Transparent reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement","volume":"162","author":"Collins","year":"2015","journal-title":"Ann Intern Med"},{"key":"B65","unstructured":"A Study of Dostarlimab in Untreated Dmmr\/MSI-H Locally Advanced Rectal Cancer (AZUR-1)"},{"key":"B66","unstructured":"Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR\/MSI-H locally advanced rectal cancer\n          \n          \n          \n          2026"},{"key":"B67","unstructured":"Pd1 Antibody Sintilimab \u00b1 Chemoradiotherapy for Locally Advanced Rectal Cancer"},{"key":"B68","unstructured":"Neoadjuvant Tisleizumab(BGB-A317) for dMMR\/MSI-H Non-late Stage CRC Patients Before Surgery"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1908199\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T11:40:27Z","timestamp":1787658027000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1908199\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":68,"alternative-id":["10.3389\/fonc.2026.1908199"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1908199","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]},"article-number":"1908199"}}